Pneumagen logo.jpg
Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference
23 mai 2024 07h00 HE | Pneumagen Ltd
 Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on...
Pneumagen logo.jpg
Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024
02 mai 2024 07h00 HE | Pneumagen Ltd
Data to be presented in oral and ePoster presentations St Andrews, UK – 2 May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
30 avr. 2024 10h00 HE | RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
Jane Wright-Mitchell
RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board
25 avr. 2024 10h00 HE | RS BioTherapeutics
RS BioTherapeutics is pleased to announce the addition of Jane Wright-Mitchell, Pharm.D., J.D. to the RS BioTherapeutics Business Advisory Board.
Global Interventional Pulmonology Market
Global Interventional Pulmonology Market Analysis Report 2024-2028: Robotic Bronchoscopy is Emerging as a Game Changer in the $5+ Billion Industry
16 avr. 2024 07h32 HE | Research and Markets
Dublin, April 16, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Pulmonology Market: Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ...
RS BioTherapeutics Logo.jpg
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18 mars 2024 11h30 HE | RS BioTherapeutics
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
Research Nester Logo.jpg
Chronic Disease Management Market revenue to reach USD 27 Billion by 2035, says Research Nester
13 mars 2024 07h30 HE | Research Nester
New York, March 13, 2024 (GLOBE NEWSWIRE) -- The global chronic disease management market size is projected to grow at a CAGR of over ~13% from 2023 to 2035. The market is expected to garner a...
Monaghan Medical Corporation
Monaghan Medical Corporation Attains ISO 14001 Certification for Environmental Management Excellence
27 févr. 2024 07h00 HE | Monaghan Medical Corporation
Monaghan Medical Corporation is proud to have achieved ISO 14001 certification
Regeneron Logo.jpg
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
23 févr. 2024 01h00 HE | Regeneron Pharmaceuticals, Inc.
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...